Acousia Therapeutics

Executive Summary

Acousia Therapeutics GmbH is a privately held German biotech company focused on developing novel small molecule therapies for sensorineural hearing loss (SNHL), a condition affecting millions worldwide with limited treatment options. Founded in 2012 and based in Tübingen, the company's lead candidate, ACOU085 (bimokalner), is currently in Phase 2 clinical trials. ACOU085 targets the potassium channel KCNQ4, which is critical for maintaining ion homeostasis in inner ear hair cells. By enhancing channel function, the drug aims to preserve and improve natural hearing, addressing a significant unmet medical need. The Phase 2 study (ACOU085-201) is a randomized, double-blind, placebo-controlled trial evaluating safety and efficacy in patients with moderate SNHL. Interim data have suggested potential benefit in speech perception, and full results are anticipated in late 2026. Acousia has received support from the German Federal Ministry of Education and Research and has a strong intellectual property portfolio. The company is actively seeking partnerships for further development and commercialization. Given the large patient population and lack of approved disease-modifying therapies for SNHL, ACOU085 represents a potentially transformative approach. However, as a private company with limited public information, investment carries higher risk. The upcoming readout will be a critical milestone.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data Readout for ACOU08560% success
• H1 2027Strategic Partnership or Licensing Deal30% success
• 2026New Financing Round50% success